Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

SODIUM THIOSULFATE INJECTION USP 250 MG — DIN 02428393

SODIUM THIOSULFATE : 250 MG · HOPE PHARMACEUTICALS LTD · SOLUTION · wholesale supply in Canada

Health Canada status: MARKETED

What is SODIUM THIOSULFATE INJECTION USP?

SODIUM THIOSULFATE INJECTION USP 250 MG contains SODIUM THIOSULFATE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02428393, held by HOPE PHARMACEUTICALS LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 23-Nov-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is SODIUM THIOSULFATE INJECTION USP used for?

Sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be life-threatening.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Is there a generic Thiosulphate in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

4 holders have a Canadian DIN containing Thiosulphate, across 4 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
HOPE PHARMACEUTICALS LTD11SODIUM THIOSULFATE INJECTION USPSourceable in Canada
PFIZER CANADA ULC11SODIUM THIOSULFATE INJECTION USPSourceable in Canada
SEAFORD PHARMACEUTICALS INC11SEACALPHYXSourceable in Canada
DAVID BULL LABORATORIES (PTY) LTD.10SODIUM THIOSULFATE INJ 25% USPNo marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label250 MG
Dosage formSOLUTION
RouteINTRAVENOUS
Pack configuration (monograph)50 mL glass vial containing 12.5 grams of sodium thiosulfate. Single dose vial.
StorageStore at controlled room temperature between 15°C and 30°C. Protect from direct light. Do not freeze.

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Substance and classification

Active substanceThiosulphate
ATC codeV03AB06
AHFS class84:80.00
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02428393
DIN (unpadded, as printed on some documents)2428393
Brand nameSODIUM THIOSULFATE INJECTION USP
Generic / active ingredientSODIUM THIOSULFATE : 250 MG
Market authorization holderHOPE PHARMACEUTICALS LTD
Health Canada scheduleEthical
ATC codeV03AB06
ATC anatomical main groupV — Various
ATC therapeutic subgroupV03AB
Current statusMARKETED
Status date23-Nov-2015
Original market date2014-09-16 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

How is it administered?

Adults: 50 mL (12.5 g) IV immediately following sodium nitrite. Children: 1 mL/kg (250 mg/kg) not to exceed 50 mL. Administer by slow intravenous injection.

Included because it drives pack selection and wastage. Consult the monograph.

Contraindications

None.

Warnings and precautions

May contain trace sulfites. Monitor blood pressure during infusion; decrease rate if hypotension occurs. Monitor for 24-48 hours for recurrent toxicity.

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

3 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
SEACALPHYX250 MGSOLUTIONSEAFORD PHARMACEUTICALS INCMARKETED02386666
SODIUM THIOSULFATE INJECTION USP250 MGSOLUTIONPFIZER CANADA ULCMARKETED02137186
SODIUM THIOSULFATE INJ 25% USP250 MGLIQUIDDAVID BULL LABORATORIES (PTY) LTD.CANCELLED POST MARKET01908820

2 · Same class — other molecules in ATC V03AB

MoleculeCanadian brandsDINsMarketedSourceable
NaloxoneINJECTABLE NALOXONE HYDROCHLORIDE · KLOXXADO · NALOXONE HCL INJECTION - 0.4MG/ML USP · NALOXONE HCL INJECTION - 1MG/ML USP · +11 more2612Yes
SugammadexBRIDION · PMS-SUGAMMADEX · SUGAMMADEX · SUGAMMADEX INJECTION · +1 more144Yes
ThiosulphateSEACALPHYX · SODIUM THIOSULFATE INJ 25% USP · SODIUM THIOSULFATE INJECTION USP43Yes
Methylthioninium ChlorideMETHYLENE BLEU LIQ 2% · METHYLENE BLUE INJ 1% · METHYLENE BLUE INJ 1% USP · METHYLENE BLUE INJ 10MG/ML USP · +3 more112Yes
FlumazenilANEXATE INJ 0.1MG/ML · FLUMAZENIL INJECTION · FLUMAZENIL INJECTION SDZ · FLUMAZENIL INJECTION, USP · +1 more62Yes
ProtaminePROTAMINE SULFATE INJ 10MG/ML USP · PROTAMINE SULFATE INJECTION USP · PROTAMINE SULFATE INJECTION, USP42Yes
FomepizoleANTIZOL · FOMEPIZOLE FOR INJECTION22Yes
HydroxocobalaminCYANOKIT21Yes
Digitalis AntitoxinDIGIBIND · DIGIFAB21Yes
IdarucizimabPRAXBIND11Yes

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC V03A

ATC subgroupMoleculesDINsMarketed
V03ACDeferasirox · Deferiprone · Deferoxamine5744
V03ANCarbon Dioxide · Combination · Helium · Medical Air · Medical Gases · +2 more11243
V03AECalcium Acetate · Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia · Lanthanum Carbonate · Patiromer Calcium · Polystyrene Sulphonate · +3 more4019
V03AFAmifostine · Calcium Folinate · Dexrazoxane · Mesna · Palifermin · +1 more3416
V03AHDiazoxide21
V03AXCobicistat · Difelikefalin · Other Therapeutic Products81
V03AZEthanol10

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for SODIUM THIOSULFATE INJECTION USP

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02428393. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.